|Bid||44.74 x 800|
|Ask||44.87 x 1400|
|Day's Range||42.01 - 45.66|
|52 Week Range||27.65 - 133.82|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for GH
It's a bit early for investors to jump the ship regarding Guardant because the biotech stock still has plenty of good long-term prospects. The test will compete with the Galleri blood-based cancer screening by the Grail unit of Illumina and a the Cologuard fecal screening by Exact Sciences. Investors are also watching the outcome of a lawsuit, filed in March by Illumina, that claims that Guardant and two of its founders -- former employees of Illumina -- used Illumina's propriety information to help them launch Guardant.
Billions of dollars have been poured into companies seeking early detection of cancer through common blood draws.
The recent price decline of 49% in Guardant Health, Inc.'s ( NASDAQ:GH ) stock may have disappointed insiders who...